Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1213857

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1213857

Anticonvulsant Drugs Market, by Drug Class, by Route of Administration, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

PUBLISHED:
PAGES: 170 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Anticonvulsants are a broad class of drugs used to treat epileptic seizures. Since many anticonvulsants tend to operate as mood stabilizers, they are also being used more frequently to treat neuropathic pain, bipolar disorder, and borderline personality disorder. Anticonvulsants, including gabapentin, carbamazepine, and valproic acid, are believed to alleviate chronic pain by obstructing sodium (valproate and the gabapentanoids) or calcium (carbamazepine and Oxcarbazepine) channels at the cellular neuronal level. This suppresses spontaneous electrical activity and restores the normal threshold to depolarization of hypersensitive nociceptive neurons without affecting normal nerve conduction.

Patients with neuropathic pain and mood disorders benefit most from these drugs. Anticonvulsant drugs are classified as either first-generation (classic) agents or second-generation agents. Second-generation anticonvulsants are usually better tolerated and have a broader therapeutic range than classic anticonvulsant drugs. The choice of drug is guided by the type of seizure. First-line treatment for focal seizures includes lamotrigine or levetiracetam, while valproate is used for generalized seizures. While all anticonvulsants have dose-dependent side effects on the central nervous system (e.g., somnolence, nausea), select agents also have other side effects (e.g., gingival hyperplasia caused by phenytoin).

Market Dynamics

Increasing prevalence of epilepsy is expected to propel the market growth over the forecast period. For instance, according to the World Health Organization, in February 2022, epilepsy is one of the most common neurological diseases globally, which affects around 50 million people. Nearly 80% of people with epilepsy live in low- and middle-income countries. According to the same source, it is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated.

Key features of the study:

  • This report provides an in-depth analysis of the global anticonvulsant drugs market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anticonvulsant drugs market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global anticonvulsant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticonvulsant drugs market

Detailed Segmentation:

  • Global Anticonvulsant Drugs Market, By Drug Class:
    • Barbiturates
    • Benzodiazepines
    • Aromatic allylic alcohols
    • Carboxamides
    • Triazine
    • AMPA receptor antagonists
    • Carbamate
    • Hydantoin
    • Fatty Acid Derivative
    • GABA analogs
    • Valproylamides
    • Others (Propionates, Oxazolidinediones, etc.)
  • Global Anticonvulsant Drugs Market, By Route of Administration:
    • Enteral
    • Parenteral
  • Global Anticonvulsant Drugs Market, By Indication:
    • Epilepsy
    • Neuropathic pain
    • Anxiety
    • Fibromyalgia
    • Bipolar Disorder
    • Others (Borderline personality disorder, etc.)
  • Global Anticonvulsant Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anticonvulsant Drugs Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Novartis AG
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • GSK plc.
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Zogenix
    • Dr. Reddy's Laboratories Ltd.
    • Alkem Labs
    • SK BIOPHARMACEUTICALS
    • Eisai Co., Ltd
    • Angelini S.p.a.
    • Sun Pharmaceutical Industries Ltd.
    • UCB S.A.
    • Unichem Laboratories
    • Jazz Pharmaceuticals, Inc.
    • Neuropathix, Inc.
    • Xenon Pharmaceuticals, Inc.
    • SK Life Science, Inc.
    • Sumitomo Pharma Co., Ltd
    • Bausch Health Companies Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI2516

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Indication
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
    • Market Opportunity Map

3. Global Anticonvulsant Drugs Market Insights

  • Drivers
  • Restraints
  • Opportunity
  • Impact Analysis
  • Pipeline Analysis
  • PEST Analysis
  • Key Developments
  • Regulatory Scenario
  • Merger & Acquisition Scenario
  • Pricing Analysis
  • Brand Mapping

4. Global Anticonvulsant Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

  • COVID-19 Epidemiology
  • Impact On Supply And Demand
  • Impact on Clinical Trials

5. Global Anticonvulsant Drugs Market, By Drug Class, 2017 - 2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Barbiturates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Benzodiazepines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Aromatic allylic alcohols
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Carboxamides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Triazine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • AMPA receptor antagonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Carbamate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Hydantoin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Fatty Acid Derivative
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • GABA analogs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Valproylamides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Others (Propionates, Oxazolidinediones, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

6. Global Anticonvulsant Drugs Market, By Route of Administration, 2017 - 2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Enteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

7. Global Anticonvulsant Drugs Market, By Indication, 2017 - 2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Epilepsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Neuropathic pain
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Anxiety
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Fibromyalgia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Bipolar Disorder
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Others (Borderline personality disorder, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

8. Global Anticonvulsant Drugs Market, By Distribution Channel, 2017 - 2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

9. Global Anticonvulsant Drugs Market, By Region, 2017 - 2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Region at Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
    • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
    • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
    • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
    • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
    • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
    • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017-2030, (US$ Million)
  • South Africa
  • Central Africa
  • North Africa

10. Company Profiles

  • Novartis AG*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Zogenix
  • DR. Reddy's Laboratories Ltd.
  • Alkem Labs
  • SK BIOPHARMACEUTICALS
  • Eisai Co., Ltd
  • Angelini S.p.a.
  • Sun Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Unichem Laboratories
  • Jazz Pharmaceuticals, Inc.
  • Neuropathix, Inc.
  • Xenon Pharmaceuticals, Inc.
  • SK Life Science, Inc.
  • Sumitomo Pharma Co., Ltd
  • Bausch Health Companies Inc.

11. Section

  • Research Methodology
  • About us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!